X0202 SCHEDULE 13G 0002062816 XXXXXXXX LIVE Ordinary Shares, par value of NIS $0.0000769 07/28/2026 0001638097 Entera Bio Ltd. M40527109 Kiryat Hadassah Minrav Building - Fifth Floor Jerusalem L3 9112002 Rule 13d-1(c) TCG Crossover GP III, LLC b DE 0 12254901 0 12254901 12254901 N 7.1 OO These securities are held of record by TCG Crossover III (as defined in Item 2(a) below). TCG Crossover GP III (as defined in Item 2(a) below) is the general partner of TCG Crossover III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP III and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 172,251,449 ordinary shares, as follows: (a) 49,290,234 ordinary shares outstanding as of May 19, 2026, as reported by the Issuer (as defined in Item 1(a) below) in its definitive proxy statement, filed with the United States Securities and Exchange Commission (the Commission) on June 3, 2026 (the Proxy Statement), plus (b) 122,961,215 ordinary shares issued in a private placement transaction that closed on July 28, 2026, as reported in the Issuer's Current Report on Form 8-K, filed with the Commission on July 28, 2026 (the Private Placement). TCG Crossover Fund III, L.P. b DE 0 12254901 0 12254901 12254901 N 7.1 PN These securities are held of record by TCG Crossover III. TCG Crossover GP III is the general partner of TCG Crossover III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP III and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 172,251,449 ordinary shares, as follows: (a) 49,290,234 ordinary shares outstanding as of May 19, 2026, as reported by the Issuer in the Proxy Statement, plus (b) 122,961,215 ordinary shares issued in the Private Placement. Chen Yu b X1 0 12254901 0 12254901 12254901 N 7.1 IN These securities are held of record by TCG Crossover III. TCG Crossover GP III is the general partner of TCG Crossover III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP III and may be deemed to share voting, investment and dispositive power with respect to these securities. Based on 172,251,449 ordinary shares, as follows: (a) 49,290,234 ordinary shares outstanding as of May 19, 2026, as reported by the Issuer in the Proxy Statement, plus (b) 122,961,215 ordinary shares issued in the Private Placement. Entera Bio Ltd. Kiryat Hadassah, Minrav Building - Fifth Floor, Jerusalem, Israel 9112002 This joint statement on Schedule 13G is being filed by TCG Crossover Fund III, L.P. (TCG Crossover III), TCG Crossover GP III, LLC (TCG Crossover GP III, and together with TCG Crossover III, the Reporting Entities) and Chen Yu (the Reporting Individual). The Reporting Entities and the Reporting Individual are collectively referred to as the Reporting Persons. The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person's pecuniary interest therein. The address of the principal business office of each Reporting Person is 245 Lytton Ave., Suite 350, Palo Alto, CA 94301. TCG Crossover GP III is a limited liability company organized under the laws of the State of Delaware. TCG Crossover III is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America. Y See Row 9 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein. See Row 11 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein. See Row 5 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein. See Row 6 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein. See Row 7 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein. See Row 8 of the cover page for each Reporting Person and the corresponding comments. Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his or its pecuniary interest therein. Y N Under certain circumstances set forth in the limited partnership agreement of TCG Crossover III and the limited liability company agreement of TCG Crossover GP III, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit 1 - Joint Filing Agreement TCG Crossover GP III, LLC /s/ Craig Skaling 08/04/2026 TCG Crossover Fund III, L.P. /s/ Craig Skaling 08/04/2026 Chen Yu /s/ Craig Skaling 08/04/2026